

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8622)

POSTPONEMENT OF THE EXTRAORDINARY GENERAL MEETING AND CHANGE OF BOOK CLOSURE PERIOD AND RECORD DATE

Reference is made to the circular (the “**Circular**”) and notice (the “**EGM Notice**”) of Huakang Biomedical Holdings Company Limited (the “**Company**”) dated 22 December 2025 in relation to, among other things, the date of the Company’s extraordinary general meeting (the “**EGM**”) and details of the resolution to be considered at the EGM. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular and the EGM Notice.

POSTPONEMENT OF THE EGM

The Board hereby announces that the EGM, which was originally scheduled to be held at 11:00 a.m. on Thursday, 8 January 2026, will be rescheduled to be held at 11:00 a.m. on Thursday, 15 January 2026 due to work arrangement coordination of the Company. The resolution set out in the EGM Notice to be proposed at the EGM will remain unchanged, and such resolution will be proposed at the rescheduled EGM. The venue of the EGM will remain unchanged at Suite 1004, 10th Floor, Chinachem Golden Plaza, No. 77 Mody Road, No. 16 Science Museum Road, Kowloon, Hong Kong.

Save for the aforesaid changes, the proxy forms of the EGM (the “**Proxy Form**”), which have been despatched to the Shareholders on 22 December 2025 and the EGM Notice, shall remain valid for the rescheduled EGM. Shareholders who have yet to return the Proxy Form are required to complete and return the Proxy Form in accordance with the instructions printed thereon to the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 48 hours before the time appointed for the meeting (i.e. not later than 11:00 a.m. on Tuesday, 13 January 2026 (Hong Kong time)). For the avoidance of doubt, any Proxy Form duly completed and returned in accordance with the instructions printed thereon remains valid for the rescheduled EGM and the relevant Shareholders are not required to return another Proxy Form.

CHANGE OF BOOK CLOSURE PERIOD AND RECORD DATE

The original book closure period from Monday, 5 January 2026 to Thursday, 8 January 2026, both days inclusive, will be changed due to the rescheduled EGM. Accordingly, for the purpose of determining the entitlement to attend and vote at the rescheduled EGM, the register of members of the Company will be closed from Monday, 12 January 2026 to Thursday, 15 January 2026, both days inclusive, during which period no transfer of the shares of the Company will be registered. In order to be eligible to attend and vote at the rescheduled EGM, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Friday, 9 January 2026. The record date for ascertaining Shareholders' entitlement to attend and vote at the rescheduled EGM is Thursday, 15 January 2026.

Saved as disclosed above, all other information and contents set out in the Circular, EGM Notice and Proxy Form remain unchanged. This announcement is supplemental to and should be read in conjunction with the Circular, EGM Notice and the Proxy Form.

On behalf of the Board
Huakang Biomedical Holdings Company Limited
Zhang Yujing
Co-Chairman and Executive Director

Hong Kong, 23 December 2025

As at the date of this announcement, the Executive Directors are Ms. Zhang Yujing, Dr. Zhou Xunyong, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; the Non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company's website at www.huakangbiomedical.com.